Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
Key Highlights
- ➤Ryoncil webinar highlighted first-line use after steroids for pediatric acute graft-versus-host disease
- ➤Dr. Susan Prockop discussed Ryoncil case studies and pivotal-trial results
- ➤Ryoncil is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older
- ➤Mesoblast develops additional cell therapies for adult graft-versus-host disease, inflammatory bowel disease, heart failure, and chronic low back pain
Expert Statements
Susan Prockop, Associate Professor at Harvard Medical School; Attending Physician and Director at Boston Children’s Hospital
“Ryoncil® (remestemcel-L-rknd) as a new treatment paradigm in the management of acute graft-versus-host disease”
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar this week titled “The Graft-versus-Host Disease Exchange - Expert Perspectives on Evolving Clinical Practice” with leading pediatric transplant and cellular-therapy specialist Dr. Susan Prockop, Associate Professor, Harvard Medical School; Attending Physician & Director, Boston Children's Hospital. Dr. Prockop provided an overview of Ryoncil(®) (remestemcel-L-rknd)(1) as a new treatment paradigm in the management of acute graft-versus-host disease, its use as first line after steroids, highlighted case studies, and discussed results from pivotal trials.
A replay of the webcast can be accessed via: GvHD Exchange Nov2026
Get started
Create a free account to read the full story.